Genmab reports trial results for ovarian cancer drug candidate
Genmab A/S has reported positive trial results for its drug candidate rinatabart sesutecan (Rina-S) in platinum-resistant ovarian cancer patients. The Phase 1/2 RAINFOL-01 trial, which enrolled 109 patients, showed a confirmed objective response rate of 45.9% and a median duration of response of 12.1 months. Over half of the patients had received three or four prior lines of therapy, and no safety signals for certain adverse events were observed.
Rina-S is an antibody-drug conjugate targeting the folate receptor alpha and is part of Genmab's clinical development program for various gynecologic cancers.
Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
